38 active not recruiting. 38 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Active not recruiting 38 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 153 | 2025-05-29 | 2026-08-24 |
| PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PD-1 Inhibitors - Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Active not recruiting | Fujian Medical University Union Hospital | 40 | 2025-05-01 | 2026-04-21 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Sonrotoclax, Zanubrutinib, Venetoclax - CLL | Phase 3 | Active not recruiting | BeOne Medicines | 652 | 2023-11-11 | 2026-10-14 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2023-03-16 | 2026-03-16 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA vaccine - HIV, Organ Transplantation | Phase 3 | Active not recruiting | Monash University | 960 | 2022-12-01 | 2025-10-03 |
| A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | AstraZeneca | 607 | 2022-09-12 | 2026-09-02 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor - Acute Lymphoblastic Leukemia, Myeloblastic Leukemia | Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 56 | 2022-08-23 | 2023-09-28 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T, Standard-of-Care - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 3 | Active not recruiting | Orca Biosystems, Inc. | 187 | 2022-06-21 | 2026-03-04 |
| Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures Remimazolam - Pediatric ALL | Phase 2 / Phase 3 | Active not recruiting | Acacia Pharma Ltd | 100 | 2021-11-15 | 2025-07-01 |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 282 | 2021-09-23 | 2026-09-25 |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 600 | 2021-09-20 | 2026-01-29 |
| Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Ponatinib + Blinatumomab, Chemotherapy + Imatinib - Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult | Phase 3 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 236 | 2021-09-08 | 2025-01-23 |
| Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Idelalisib, Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 238 | 2021-03-09 | 2026-04-24 |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) Ibrutinib, Venetoclax, Obinutuzumab - Chronic Lymphoid Leukemia | Phase 3 | Active not recruiting | German CLL Study Group | 897 | 2021-03-01 | 2026-04-30 |
| Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia Acalabrutinib, Rituximab, Chlorambucil - Untreated Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | AstraZeneca | 155 | 2020-01-20 | 2026-09-14 |
| An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Venetoclax - Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | AbbVie | 165 | 2019-09-06 | 2026-05-13 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-10-01 |
Showing 20 of 38. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia, Biphenotypic, Acute (6) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Myelodysplastic Syndromes (4) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4) · Hematologic Diseases (3) · Lymphoma, B-Cell (3) · Leukemia (2) · Leukemia, B-Cell (2) · Multiple Myeloma (2) · Anemia (1)
Hemic and Lymphatic Diseases (38) · Immune System Diseases (38) · Immunoproliferative Disorders (38) · Lymphatic Diseases (38) · Lymphoproliferative Disorders (38) · Neoplasms by Histologic Type (38) · Neoplasms (37) · Leukemia (36) · Hematologic Diseases (35) · Chronic Disease (21) · Disease Attributes (21) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Leukemia, B-Cell (20)
Rituximab (12) · Cyclophosphamide (11) · venetoclax (10) · obinutuzumab (9) · pegaspargase (9) · Cytarabine (8) · Methotrexate (8) · ibrutinib (8) · Bendamustine Hydrochloride (7) · Dexamethasone (7) · Mercaptopurine (7) · Vincristine (7) · Calcium Dobesilate (6) · Doxorubicin (6) · Etoposide (6)
National Cancer Institute (NCI) (7) · Acerta Pharma BV (4) · Children's Oncology Group (3) · Loxo Oncology, Inc. (3) · AstraZeneca (2) · BeOne Medicines (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Janssen Research & Development, LLC (2) · AbbVie (1) · Acacia Pharma Ltd (1) · Assistance Publique - Hôpitaux de Paris (1) · BeiGene (1) · Children's Cancer Group, China (1) · Dana-Farber Cancer Institute (1) · Fujian Medical University Union Hospital (1)
United States (28) · Australia (19) · Canada (17) · France (15) · Poland (14) · Spain (14) · Israel (13) · Italy (13) · China (12) · United Kingdom (12) · Belgium (11) · Czechia (11) · Sweden (11) · Taiwan (11) · Germany (10)
Jennifer A Woyach (2) · Tait D Shanafelt (2) · Andrea Biondi (1) · Arnon Kater (1) · Barbara Eichhorst (1) · David T Teachey (1) · Etan Orgel (1) · Heather J Symons (1) · Hiroto Inaba, MD, PhD (1) · James H McMahon, MBBS PhD (1)
PMID 38598745, PMID 39563886, PMID 10627444, PMID 16421426, PMID 17003366, PMID 19433688, PMID 23389497, PMID 24344215, PMID 26887549, PMID 30501481, PMID 31365801, PMID 31875923, PMID 32305093, PMID 32459600, PMID 32589970, PMID 33054121, PMID 33439748, PMID 33709202, PMID 33796237, PMID 33844429, PMID 34274940, PMID 34310172, PMID 34398557, PMID 34534514, PMID 34865212, PMID 34933343, PMID 35271306, PMID 35427411, PMID 35478711, PMID 35810754, PMID 36102212, PMID 36603187, PMID 37315225, PMID 37390310, PMID 37752878, PMID 37801678, PMID 37944541, PMID 38215395, PMID 38319255, PMID 38457359, PMID 38502198, PMID 38754046, PMID 39020446, PMID 39047240, PMID 39647999, PMID 39651791, PMID 39976417, PMID 40198878, PMID 40396505, PMID 40448577
2023 (4), U10CA180886 (4), 2017 (3), U10CA180820 (3), 2014 (2), U10CA021115 (2), U10CA180821 (2), U24CA196172 (2), 2015 (1), 2018 (1), 2019 (1), K23CA178183 (1), R01CA183444 (1), R01CA193541 (1), U10CA031946 (1)